← All trials
NCT03187834
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 4, 2017
- Primary completion
- Sep 1, 2018
- Completion date
- Sep 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 360
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- University of California, San FranciscoLead sponsor
- University of HeidelbergCollaborator
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoReponsible party - principal investigator
- University of California, San FranciscoStudy director
- Centre de Recherche en Sante de Nouna, Burkina FasoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.